VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Vericel Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$40.37+0.24 (+0.60%)
Close on Oct 19, 2026
- Market cap
- $2.11B
- P/E (TTM)
- 96.1
- Dividend yield
- –
Vericel Corp revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2014 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M A C I Implants and kits | $239.51M | $197.31M | $164.80M | $131.97M | $111.55M | $94.43M | $91.62M | – | – | – | 86.7% | +21.4% |
| Other revenue | – | – | – | – | – | – | $0 | $0 | $1.16M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Vericel's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.